XV LVAS Ventilation Report

A new view of lung health

The XV Technology Lung Ventilation Analysis Software (XV LVAS Ventilation) provides a state-of-the-art, non-invasive way of understanding regional lung motion and airflow. It enables highly-detailed maps of both the patterns of lung motion and pulmonary function, with functional deficits detected through local (regional) differences in movement.

The XV LVAS delivers information not available via other modalities.

Measuring regional ventilation, the report enables physicians to detect areas of high and low ventilation with pinpoint accuracy. Ventilation is calculated for all parts of the lung, in all phases of the breath.

A color-coded visualization is generated, showing both coronal and axial slices at peak inspiration, plus a 4-dimensional animation. Red depicts regions of low ventilation, green regions of average ventilation and blue regions of high ventilation.

Screen Shots – Click to Enlarge


Diagnostic Support

Earlier diagnosis and treatment can be assisted by more sensitive and accurate assessments of regional lung ventilation. For chronic and progressive lung diseases with dyspnea, poor exercise tolerance, chronic cough with or without sputum production, and wheezing to respiratory failure involving the airways and/or pulmonary parenchyma that results in changes in regional airflow or ventilatory obstruction. Test results are available quickly which means that physicians are making management decisions with the assistance of additional innovative functional insights into the status of lung health. Physicians are easily able to communicate treatment plans and management options with patients and their care providers.

Patient and Treatment Monitoring

Low radiation makes XV LVAS an ideal solution for monitoring disease progression and therapeutic effectiveness in indications such as COPD and CF. Importantly XV LVAS helps clinicians confirm management course since improvements in clinical symptoms do not necessarily correlate with spirometric responses to therapy or reduction of long-term decline in FEV1. Similarly, exposure or infection can lead to fibrotic changes in how airflows through regions of the lung that can significantly affect health and well being. The use of functional lung imaging is also well suited for monitoring the long-term effects of COVID-19.

Surgical Planning

A more intricate and sensitive analysis of a patient’s lung health will allow the optimization of surgical options. Presurgical planning and postsurgical imaging of regional lung function to determine and monitoring procedures ensures comprehensive, innovative and supportive care. The use of functional imaging and dynamic regional ventilation reports facilitate effective multidisciplinary management of both routine and complex interventions and procedures. Specific residual regional lung functional deficit can be identified for follow-up or correction.

Clinical Trial Support

XV LVAS provides more sensitivity, repeatable measures and novel endpoints for new clinical trials. Knowledge creation to improves diagnosis and therapeutic success for patients is with acute and chronic pulmonary diseases. Pioneering medical research means patients have access to state-of-the-art diagnostic and treatments. Functional lung imaging as a companion diagnostic for innovative therapies provides additional high quality illustrations that can assist in maximizing therapeutic engagement.

Intensive Care

Advanced critical care procedures such as invasive mechanical ventilation and ECMO are utilized to stabilized ventilation often due to inhomogeneous lung injury or infection. Accurate quantification of regional lung ventilation may assist critical care physicians with their decisions regarding ventilator utilization and therapy optimisation to potentially reduce the risk of ventilator induced lung injury, shorten time on vent and determine ventilator liberation strategy.

Now that the XV LVAS has FDA clearance, 4DMedical is in the process of applying for regulatory clearance in other jurisdictions.